US-based health product maker Elysium Health has secured $40m from investors including medical research firm Mayo Clinic through a combination of series C equity and debt financing.
Mayo Clinic, which invested through subsidiary Mayo Clinic Ventures, joined Gisev Family Office, which led the round, General Catalyst, Morningside Ventures and Breyer Capital while Western Technology Investment provided the debt financing.
Elysium partners scientists and clinicians to access cutting-edge research that could form the basis for new consumer health products.
The company’s products include Basis, a dietary supplement that supports healthy genetic function. It will channel the funding into expanding its product range, which is set to include health tests.
The round comes after Elysium agreed a $5m credit facility with Silicon Valley Bank in mid-2017, and a $20m series B round led by General Catalyst in 2016 that included private investor Robert Nelson, at a reported $157m valuation.
The company had previously raised $6.2m in series A funding according to regulatory documents seen by TechCrunch. Morningside Ventures and Breyer Capital were also named as returning investors in the latest round.
Image courtesy of Elysium Health, Inc.
